Neurometa Therapeutics
PrivateLast Round
Accelerator
May 21, 2025
Total Funding Raised
$2.46M
Company Overview
Neurometa Therapeutics is a biotechnology company developing a novel neurometabolic approach to treating neurodegenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Neurometa Therapeutics Comparables
Compare Neurometa Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NRG Therapeutics | 81% | |
| T3D Therapeutics, Inc. | 77% | |
| Clene | 75% |
Neurometa Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Accelerator | May 21, 2025 | ||||
| Grant | Dec 10, 2022 | ||||
| Seed | Sep 22, 2020 |
Key People
Founding team and executive leadership
Neurometa Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| U.S. Department of War | Grant |
| BioInnovation Institute | Seed |
| SmiLe Venture Hub | Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 14, 2025
Grew 60% QoQ, from 10 to 16 employees.
- Oct 15, 2025
Grew 45% QoQ, from 11 to 16 employees.
Neurometa Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Neurometa Therapeutics's valuation, stock price, and market status.
Is Neurometa Therapeutics a public or private company?
Neurometa Therapeutics is a private company.
What is the current stock price of Neurometa Therapeutics?
Neurometa Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Neurometa Therapeutics worth (valuation)?
Valuation information for Neurometa Therapeutics is not publicly available.
Can I buy Neurometa Therapeutics stock?
Neurometa Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Neurometa Therapeutics's last funding round?
Neurometa Therapeutics's most recent funding round was Accelerator on May 21, 2025.
Who are the main investors in Neurometa Therapeutics?
Key investors in Neurometa Therapeutics include BioInnovation Institute.
Will Neurometa Therapeutics IPO soon?
No public IPO plans have been announced for Neurometa Therapeutics.
How can I track Neurometa Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Neurometa Therapeutics's secondary market activity and sign up for updates.